Zhong Yun-Shi, Lü Shi-Xu, Xu Jian-Min
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zhonghua Wai Ke Za Zhi. 2008 Aug 15;46(16):1229-33.
To investigate the tumor proliferation and apoptosis changes after preoperative hepatic and regional arterial infusion chemotherapy (PHRAIC) after radical colorectal cancer resection.
Five hundred and nine patients with stage II or stage III colorectal cancer from June 2001 to June 2007 were randomly assigned to PHRAIC group (n = 256) or control group (n = 253, surgery alone). Tumor proliferation and apoptosis index were evaluated in tumor tissues of the control and PHRAIC group (pre and after intervention). The survival rates were also recorded in the two groups.
There was no significant differences in sex, age, tumor location, tumor size, tumor stage, tumor differentiation and follow-up time for the two groups (P > 0.05). There was no significant differences in all the evaluation factors between the control group and PHRAIC group before intervention (P > 0.05). Before and after intervention for PHRAIC group: stage 3 necrosis rate were 3.1% and 22.7%, stage 4 necrosis rate were 0 and 13.5% (P < 0.05); label index of Ki67 were 48.6 +/- 17.1 and 38.4 +/- 13.3 (P < 0.05); expression rate of Bax, bcl-2 and survivin were 48.0% vs 77.0%, 75.0% vs 43.0%, 52.0% vs 31.6%, respectively (P < 0.05); apoptosis rate were 4.3% +/- 2.2% and 16.7% +/- 6.4%(P < 0.05). In the PHRAIC group, 42.1% +/- 11.2% of the cells in the tumor tissue were in S phase before intervention and the rate fell to 21.8% +/- 10.7% after intervention (P < 0.05); and G0-G1 phase rate of the group pre and post intervention were 35.1% +/- 12.1% and 57.1% +/- 18.1% (P < 0.05). All the patients were followed-up for a mean time of 42 +/- 14 months. For patients with stage III tumor in PHRAIC group and control group, the 5-year liver metastasis rate were 18.9% and 27.3% (P = 0.033), recurrence and metastasis rate were 26.3% and 38.0 (P = 0.024), overall survival rate were 81.0% and 60.4% (P = 0.011), median survival time were 45 and 40 months (P = 0.02); no significant differences of aforementioned factors was found in patients with stage II tumors between the two groups.
The schedule of preoperative hepatic and regional arterial infusion chemotherapy before surgery can restrain proliferation, promote apoptosis and reduce liver metastasis and improve survival rate in stage III colorectal cancer.
探讨根治性结直肠癌切除术前肝动脉及区域动脉灌注化疗(PHRAIC)后肿瘤增殖和凋亡的变化。
将2001年6月至2007年6月的509例II期或III期结直肠癌患者随机分为PHRAIC组(n = 256)和对照组(n = 253,单纯手术)。评估对照组和PHRAIC组(干预前后)肿瘤组织中的肿瘤增殖和凋亡指数。同时记录两组的生存率。
两组患者的性别、年龄、肿瘤位置、肿瘤大小、肿瘤分期、肿瘤分化程度及随访时间差异均无统计学意义(P > 0.05)。干预前,对照组和PHRAIC组所有评估因素差异均无统计学意义(P > 0.05)。PHRAIC组干预前后:3级坏死率分别为3.1%和22.7%,4级坏死率分别为0和13.5%(P < 0.05);Ki67标记指数分别为48.6±17.1和38.4±13.3(P < 0.05);Bax、bcl-2和survivin的表达率分别为48.0%对77.0%、75.0%对43.0%、52.0%对31.6%(P < 0.05);凋亡率分别为4.3%±2.2%和16.7%±6.4%(P < 0.05)。PHRAIC组干预前肿瘤组织中42.1%±11.2%的细胞处于S期,干预后该比例降至21.8%±10.7%(P < 0.05);干预前后该组G0-G1期比例分别为35.1%±12.1%和57.1%±18.1%(P < 0.05)。所有患者平均随访42±14个月。PHRAIC组和对照组III期肿瘤患者的5年肝转移率分别为18.9%和27.3%(P = 0.033),复发转移率分别为26.3%和38.0(P = 0.024),总生存率分别为81.0%和60.4%(P = 0.011),中位生存时间分别为45个月和40个月(P = 0.02);两组II期肿瘤患者上述因素差异无统计学意义。
术前肝动脉及区域动脉灌注化疗方案可抑制III期结直肠癌的增殖,促进凋亡,减少肝转移,提高生存率。